24.04.2013 - Bayer Crop Science has entered a multi-year R&D partnership with Keygene to improve traits in crops.
The German and the Dutch company announced that the scope of their first research programme is wheat, potentially to be followed by projects in oilseed rape, rice and cotton. In the collaboration, Bayer will access KeyGene’s KeySeeQ® discovery pipeline. The platform technology will be used to identify genes associated with novel traits such as drought tolerance. The genes will be then improved by KeyGene using its automated high throughput targeted mutagenesis tool KeyPoint®. Bayer will be responsible for global market introduction of the resulting new wheat varieties.
“Bayer has the goal to offer farmers tailor-made wheat varieties with improved yield and other agronomically-important traits including drought tolerance and nitrogen use efficiency,” said David Nicholson, Global R&D Head at Bayer CropScience. However, it's not an easy task to create new varieties in wheat due to its polyploidy and the involvement of many genes in such complex traits such as drought tolerance. However, improving the tolerance of wheat varieties to cope with drought and other environmental stress factors is important across the world.
Wheat is one of the most important staple crops for humans: the worldwide consumption was 704 million tons in 2011. It is expected that by 2030 farmers will face an increase of 40% in the world-wide demand for wheat. Therefore, new varieties need to provide farmers with important agricultural innovations which help them to sustainably increase yield and profitability.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.